MeCure Industries Limited, a prominent player in the human pharmaceuticals and nutraceuticals manufacturing sector, is poised to debut on the Nigerian Exchange Limited (NGX) with the listing of 4 billion ordinary shares at N2.96 per share.
This momentous development marks a significant addition to NGX’s pharmaceuticals industry landscape, contributing a substantial N11.84 billion to the market capitalization of the Exchange upon its inclusion on the Main Board.
Leveraging the potential of cutting-edge technology and innovation, MeCure Industries Plc has been at the forefront of revolutionizing the field of medicine for over a decade.
MeCure Industries is renowned for its groundbreaking work in introducing novel products driven by advancements in technology.
The company notably launched the industry’s first tablet in a capsule formulation, known as Liquitab Floatcap, a pioneering solution that has significantly impacted the healthcare sector.
Over the years, MeCure has solidified its position as an entrepreneurial and technology-focused enterprise committed to providing effective healthcare solutions for individuals combating common illnesses.
The forthcoming listing of MeCure Industries on the NGX further cements the Exchange’s status as a preferred platform for corporate entities seeking to raise capital.
In 2023 alone, the NGX has successfully secured listings from esteemed institutions such as VFD Group, Nigeria Infrastructure Debt Fund (NIDF), and Africa Plus Partners, demonstrating its dedication to promoting a conducive environment for companies to access capital in the Nigerian market.
NGX continues to enhance its appeal for businesses considering the Nigerian capital market for their fundraising requirements.
It continues to reinvent itself, working closely with policymakers and regulators to foster a conducive atmosphere for public market listings.
